 |
|
|
| |
Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): Examining Healthcare Staff Attitudes During a Hybrid III Implementation-Effectiveness Trial Implementing Cabotegravir + Rilpivirine Long-Acting Injectable (CAB + RPV LA) for People Living With HIV
|
| |
| |
EACS 2021 Oct 27-30
Cassidy Gutner1, Samia Dakhia2, Martin Gill3, Miguel Pascual-Bernaldez4, Beatriz Hernandez4, Agathe Rami5, Joaquin Portilla6, Thomas Lutz7, Marc van der Valk8, Eric Florence9, Nicola Barnes10, Owen Cooper10, Dina Filipenko10, Alison Hamilton11, Matthew Bosse1, Maggie Czarnogorski1
1ViiV Healthcare, Research Triangle Park, NC, United States; 2ViiV Healthcare, Brentford, United Kingdom; 3GlaxoSmithKline, Brentford, United Kingdom; 4ViiV Healthcare, Madrid, Spain; 5GH Lariboisiere Fernand Widal, Paris, France; 6Hospital General De Alicante, Alicante, Spain;
7Infektio Research, Frankfurt, Germany; 8Amsterdam UMC, Amsterdam, the Netherlands; 9Instituut voor Tropische Geneeskunde, Antwerp, Belgium; 10Evidera, London, United Kingdom; 11University of California Los Angeles, Los Angeles, CA, United States
|
| |
|
|
|
|
|
